OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Diana Bernardo, Thomas Bieber, Tiago Torres
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 753-764
Open Access | Times Cited: 16
Diana Bernardo, Thomas Bieber, Tiago Torres
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 753-764
Open Access | Times Cited: 16
Showing 16 citing articles:
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 48
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 48
Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan
Teppei Hagino, Akihiko Uchiyama, Marina Onda, et al.
Dermatitis (2025)
Closed Access | Times Cited: 1
Teppei Hagino, Akihiko Uchiyama, Marina Onda, et al.
Dermatitis (2025)
Closed Access | Times Cited: 1
Lebrikizumab: First Approval
Susan J. Keam
Drugs (2024) Vol. 84, Iss. 3, pp. 347-353
Closed Access | Times Cited: 7
Susan J. Keam
Drugs (2024) Vol. 84, Iss. 3, pp. 347-353
Closed Access | Times Cited: 7
A year in review: new treatments and expanded indications in dermatology in 2024
Lauren M. McGrath, Lila G. McGrath, John R. Edminister
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Lauren M. McGrath, Lila G. McGrath, John R. Edminister
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy
Teppei Hagino, Akihiko Uchiyama, Marina Onda, et al.
Dermatitis (2025)
Closed Access
Teppei Hagino, Akihiko Uchiyama, Marina Onda, et al.
Dermatitis (2025)
Closed Access
Type 2 Inflammation and Its Role in Dermatologic Diseases
Raj Chovatiya, Jason E. Hawkes, Douglas DiRuggiero, et al.
International Journal of Dermatology (2025)
Open Access
Raj Chovatiya, Jason E. Hawkes, Douglas DiRuggiero, et al.
International Journal of Dermatology (2025)
Open Access
Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis
Teppei Hagino, Akihiko Uchiyama, Keiji Kosaka, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
Teppei Hagino, Akihiko Uchiyama, Keiji Kosaka, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
A Case of Cutaneous Fungal Infection Following the Administration of Dupilumab
Shinichi Tanemura, Yoshihito Mima
Cureus (2025)
Open Access
Shinichi Tanemura, Yoshihito Mima
Cureus (2025)
Open Access
Real-World Japanese Study of the Effectiveness and Safety of Switching From Dupilumab to Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis
Teppei Hagino, Akihiko Uchiyama, Marina Onda, et al.
Dermatitis (2025)
Closed Access
Teppei Hagino, Akihiko Uchiyama, Marina Onda, et al.
Dermatitis (2025)
Closed Access
IL-13 inhibition in the treatment of atopic dermatitis – new and emerging biologic agents
Carlos Eduardo Garcez Teixeira, Orhan Yilmaz, Diana Bernardo, et al.
Journal of International Medical Research (2024) Vol. 52, Iss. 11
Open Access | Times Cited: 3
Carlos Eduardo Garcez Teixeira, Orhan Yilmaz, Diana Bernardo, et al.
Journal of International Medical Research (2024) Vol. 52, Iss. 11
Open Access | Times Cited: 3
Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
Laure Migayron, Sylvie Bordes, B. Closs, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Laure Migayron, Sylvie Bordes, B. Closs, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Current and Emerging Biologics for Atopic Dermatitis
Michael Z. Nevid, Mark Boguniewicz
Immunology and Allergy Clinics of North America (2024) Vol. 44, Iss. 4, pp. 577-594
Closed Access | Times Cited: 1
Michael Z. Nevid, Mark Boguniewicz
Immunology and Allergy Clinics of North America (2024) Vol. 44, Iss. 4, pp. 577-594
Closed Access | Times Cited: 1
Addressing Unmet Needs in Atopic Dermatitis: Evaluating Disease-Modifying Capabilities of Current and Emerging Therapies
Sarah G Brooks, Lourdes M Lopez, Kayla D. Mashoudy, et al.
Dermatitis (2024)
Closed Access
Sarah G Brooks, Lourdes M Lopez, Kayla D. Mashoudy, et al.
Dermatitis (2024)
Closed Access
Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
Jinger Lin, Min Luo, Qianwei Zhuo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Jinger Lin, Min Luo, Qianwei Zhuo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis
Luca Stingeni, Silvia Ferrucci, Paolo Amerio, et al.
Expert Opinion on Biological Therapy (2024), pp. 1-6
Open Access
Luca Stingeni, Silvia Ferrucci, Paolo Amerio, et al.
Expert Opinion on Biological Therapy (2024), pp. 1-6
Open Access
Lebrikizumab: a novel approach in managing atopic dermatitis in pediatric patients
Diana M. Ibarra Tostado, Ana C. Morfin, Mariemily A. Coronado, et al.
International Journal of Contemporary Pediatrics (2023) Vol. 10, Iss. 12, pp. 1876-1880
Open Access
Diana M. Ibarra Tostado, Ana C. Morfin, Mariemily A. Coronado, et al.
International Journal of Contemporary Pediatrics (2023) Vol. 10, Iss. 12, pp. 1876-1880
Open Access
